{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:24:42Z","timestamp":1793690682242,"version":"4.5.1"},"reference-count":100,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,17]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The fifth edition of the World Health Organization (WHO) classification and the International Consensus Classification (ICC) both include a category \"myeloid\/lymphoid neoplasms (MLN) with eosinophilia (eo) and tyrosine kinase (TK) gene fusions\u201d (WHO, MLN-TK; ICC, M\/LN-eo-TK). This rare group comprises phenotypically and prognostically heterogeneous disorders, which present a significant diagnostic challenge. The rapid and reliable identification of patients with MLN-TK may be delayed due to genetic complexity and significant phenotypic differences, including the chronic phase and primary\/secondary blast phase (BP) of myeloid, lymphoid, or mixed phenotype in the bone marrow (BP-BM) and\/or at extramedullary sites (extramedullary disease [EMD]). As a result, the entire armamentarium of conventional molecular genetic and cytogenetic techniques complemented by modern sequencing technologies, such as RNA sequencing or whole-genome sequencing, are often required to identify an underlying TK fusion. TK inhibitors (TKIs) with variable efficacy are available for all fusion genes, but a long-term favorable clinical course under TKI monotherapy is currently only observed in MLN-PDGFRA\/PDGFRB fusion genes on imatinib. Because primary\/secondary BP-BM\/EMD occurs more frequently in MLN-FGFR1\/JAK2\/FLT3\/ETV6::ABL1, a sequential combination of selective TKIs with or without prior intensive chemotherapy, rarely local radiotherapy, and\/or subsequent allogeneic hematopoietic cell transplantation should be considered.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2023022417","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T16:06:41Z","timestamp":1721837201000},"page":"1758-1768","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":34,"title":["How I diagnose and treat myeloid\/lymphoid neoplasms with tyrosine kinase gene fusions"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7718-6507","authenticated-orcid":false,"given":"Andreas","family":"Reiter","sequence":"first","affiliation":[{"name":"1Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Metzgeroth","sequence":"additional","affiliation":[{"name":"1Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5481-2555","authenticated-orcid":false,"given":"Nicholas C. P.","family":"Cross","sequence":"additional","affiliation":[{"name":"2Wessex Genomics Laboratory Service, Salisbury, United Kingdom"},{"name":"3Faculty of Medicine, University of Southampton, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2025041711220492400_bib1","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/blood-2016-10-695973","article-title":"Myeloid neoplasms with\u00a0eosinophilia","volume":"129","author":"Reiter","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2025041711220492400_bib2","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2025041711220492400_bib3","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2025041711220492400_bib4","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ajh.25945","article-title":"Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: data from 151 patients","volume":"95","author":"Rohmer","year":"2020","journal-title":"Am J Hematol"},{"issue":"9","key":"2025041711220492400_bib5","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/s41375-023-01958-1","article-title":"Myeloid\/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort","volume":"37","author":"Metzgeroth","year":"2023","journal-title":"Leukemia"},{"issue":"8","key":"2025041711220492400_bib6","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/ajh.26966","article-title":"The International Consensus Classification of eosinophilic disorders and systemic mastocytosis","volume":"98","author":"Wang","year":"2023","journal-title":"Am J Hematol"},{"issue":"1","key":"2025041711220492400_bib7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/all.15544","article-title":"Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes","volume":"78","author":"Valent","year":"2023","journal-title":"Allergy"},{"issue":"3","key":"2025041711220492400_bib8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/gcc.20235","article-title":"A\u00a0BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia","volume":"44","author":"Griesinger","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"key":"2025041711220492400_bib9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.humpath.2017.05.008","article-title":"Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)\/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase","volume":"65","author":"Montenegro-Garreaud","year":"2017","journal-title":"Hum Pathol"},{"issue":"24","key":"2025041711220492400_bib10","doi-asserted-by":"crossref","first-page":"e29179","DOI":"10.1097\/MD.0000000000029179","article-title":"A\u00a0rare cause of persistent leukocytosis with massive splenomegaly: myeloid neoplasm with BCR-PDGFRA rearrangement-case report and literature review","volume":"101","author":"Gao","year":"2022","journal-title":"Medicine (Baltim)"},{"issue":"2","key":"2025041711220492400_bib11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3324\/haematol.10980","article-title":"Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene","volume":"92","author":"Walz","year":"2007","journal-title":"Haematologica"},{"issue":"1","key":"2025041711220492400_bib12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3324\/haematol.11836","article-title":"Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion","volume":"93","author":"Lahortiga","year":"2008","journal-title":"Haematologica"},{"issue":"1","key":"2025041711220492400_bib13","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cancergencyto.2007.10.021","article-title":"Fusion of PRKG2 and SPTBN1 to the platelet-derived growth factor receptor beta gene (PDGFRB) in imatinib-responsive atypical myeloproliferative disorders","volume":"181","author":"Gallagher","year":"2008","journal-title":"Cancer Genet Cytogenet"},{"key":"2025041711220492400_bib14","first-page":"4158567","article-title":"A\u00a026-year-old female with systemic mastocytosis with associated myeloid neoplasm with eosinophilia and abnormalities of PDGFRB, t(4;5)(q21;q33)","volume":"2016","author":"Brown","year":"2016","journal-title":"Case Rep Hematol"},{"key":"2025041711220492400_bib15","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.humpath.2017.03.014","article-title":"Acute mast cell leukemia associated with t(4;5)(q21;q33)","volume":"67","author":"Wang","year":"2017","journal-title":"Hum Pathol"},{"issue":"8","key":"2025041711220492400_bib16","doi-asserted-by":"crossref","first-page":"e24707","DOI":"10.1097\/MD.0000000000024707","article-title":"Myeloid tumors accompanying systemic mastocytosis, basophilia, and abnormal platelet-derived growth factor receptor \u03b2: a case report","volume":"100","author":"Li","year":"2021","journal-title":"Medicine (Baltim)"},{"issue":"9","key":"2025041711220492400_bib17","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.6004\/jnccn.2020.0042","article-title":"Myeloid\/lymphoid neoplasms with eosinophilia and TK fusion genes, version 3.2021, NCCN clinical practice guidelines in oncology","volume":"18","author":"Gerds","year":"2020","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"1","key":"2025041711220492400_bib18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/hematology.2022000368","article-title":"Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms","volume":"2022","author":"Gotlib","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"11","key":"2025041711220492400_bib19","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/leu.2013.129","article-title":"Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid\/lymphoid neoplasms with PDGFR rearrangements in blast phase","volume":"27","author":"Metzgeroth","year":"2013","journal-title":"Leukemia"},{"issue":"13","key":"2025041711220492400_bib20","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A\u00a0tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"2025041711220492400_bib21","doi-asserted-by":"crossref","first-page":"7830","DOI":"10.1073\/pnas.0932698100","article-title":"Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome","volume":"100","author":"Griffin","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"2025041711220492400_bib22","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","article-title":"CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy","volume":"102","author":"Pardanani","year":"2003","journal-title":"Blood"},{"issue":"2","key":"2025041711220492400_bib23","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/leu.2008.309","article-title":"Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis\u00a0of patient-specific genomic DNA fusion junctions","volume":"23","author":"Score","year":"2009","journal-title":"Leukemia"},{"issue":"5","key":"2025041711220492400_bib24","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1111\/bjh.16340","article-title":"Frequent false-negative FIP1L1-PDGFRA FISH analyses of bone marrow samples from clonal eosinophilia at diagnosis","volume":"188","author":"Olsson-Arvidsson","year":"2020","journal-title":"Br J Haematol"},{"issue":"4","key":"2025041711220492400_bib25","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000528046","article-title":"False-negative testing for FIP1L1::PDGFRA by fluorescence in situ hybridization is a frequent cause of diagnostic delay","volume":"146","author":"Pongdee","year":"2023","journal-title":"Acta Haematol"},{"issue":"9","key":"2025041711220492400_bib26","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3324\/haematol.10328","article-title":"Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders","volume":"92","author":"Reiter","year":"2007","journal-title":"Haematologica"},{"issue":"8","key":"2025041711220492400_bib27","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.3324\/haematol.2017.187302","article-title":"Molecular genetic characterization of myeloid\/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2","volume":"103","author":"Baer","year":"2018","journal-title":"Haematologica"},{"issue":"5","key":"2025041711220492400_bib28","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/ajh.27287","article-title":"World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management","volume":"99","author":"Shomali","year":"2024","journal-title":"Am J Hematol"},{"issue":"11","key":"2025041711220492400_bib29","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2006-10-050054","article-title":"Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia","volume":"109","author":"Jovanovic","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2025041711220492400_bib30","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/leu.2008.310","article-title":"The molecular anatomy of the FIP1L1-PDGFRA fusion gene","volume":"23","author":"Walz","year":"2009","journal-title":"Leukemia"},{"issue":"7","key":"2025041711220492400_bib31","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1080\/10428194.2017.1397663","article-title":"Myeloid\/lymphoid neoplasms with FGFR1 rearrangement","volume":"59","author":"Strati","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2025041711220492400_bib32","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00277-021-04712-8","article-title":"Genomic and clinical findings in myeloid neoplasms with PDGFRB rearrangement","volume":"101","author":"Di Giacomo","year":"2022","journal-title":"Ann Hematol"},{"issue":"4","key":"2025041711220492400_bib33","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/s41375-019-0632-4","article-title":"Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry","volume":"34","author":"Kluin-Nelemans","year":"2020","journal-title":"Leukemia"},{"issue":"9","key":"2025041711220492400_bib34","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/ajh.24075","article-title":"KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance","volume":"90","author":"Schwaab","year":"2015","journal-title":"Am J Hematol"},{"issue":"26","key":"2025041711220492400_bib35","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1182\/blood.2019001385","article-title":"JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera","volume":"134","author":"Patel","year":"2019","journal-title":"Blood"},{"issue":"18","key":"2025041711220492400_bib36","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1182\/bloodadvances.2021004237","article-title":"A\u00a0novel activating JAK1 mutation in chronic eosinophilic leukemia","volume":"5","author":"Shomali","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"2025041711220492400_bib37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000518737","article-title":"Chronic eosinophilic leukaemia associated with JAK2 Exon 13 insertion\/deletion mutations","volume":"145","author":"Lafferty","year":"2022","journal-title":"Acta Haematol"},{"issue":"2","key":"2025041711220492400_bib38","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41375-018-0342-3","article-title":"Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia","volume":"33","author":"Cross","year":"2019","journal-title":"Leukemia"},{"issue":"6","key":"2025041711220492400_bib39","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/ajh.27306","article-title":"Involvement of the JAK-STAT pathway in the molecular landscape of tyrosine kinase fusion-negative hypereosinophilic syndromes: a nationwide CEREO study","volume":"99","author":"Groh","year":"2024","journal-title":"Am J Hematol"},{"issue":"8","key":"2025041711220492400_bib40","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/modpathol.2016.75","article-title":"Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified","volume":"29","author":"Wang","year":"2016","journal-title":"Mod Pathol"},{"issue":"5","key":"2025041711220492400_bib41","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/s41375-023-01859-3","article-title":"Comprehensive response criteria for myeloid\/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group","volume":"37","author":"Shomali","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"2025041711220492400_bib42","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/bjh.14748","article-title":"Molecular monitoring of patients with ETV6-PDGFRB rearrangement: implications for therapeutic adaptation","volume":"182","author":"Bidet","year":"2018","journal-title":"Br J Haematol"},{"issue":"4","key":"2025041711220492400_bib43","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.hoc.2017.04.009","article-title":"Tyrosine kinase inhibitors in the treatment of eosinophilic neoplasms and systemic mastocytosis","volume":"31","author":"Gotlib","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"issue":"6","key":"2025041711220492400_bib44","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/sj.leu.2404662","article-title":"Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma","volume":"21","author":"Metzgeroth","year":"2007","journal-title":"Leukemia"},{"issue":"9","key":"2025041711220492400_bib45","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00277-017-3067-x","article-title":"Imatinib in myeloid\/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase","volume":"96","author":"Jawhar","year":"2017","journal-title":"Ann Hematol"},{"issue":"8","key":"2025041711220492400_bib46","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.leukres.2005.11.011","article-title":"FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature","volume":"30","author":"Pardanani","year":"2006","journal-title":"Leuk Res"},{"issue":"9","key":"2025041711220492400_bib47","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3324\/haematol.11420","article-title":"The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study","volume":"92","author":"Baccarani","year":"2007","journal-title":"Haematologica"},{"issue":"5","key":"2025041711220492400_bib48","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1365-2141.2008.07294.x","article-title":"Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study","volume":"143","author":"Metzgeroth","year":"2008","journal-title":"Br J Haematol"},{"issue":"4","key":"2025041711220492400_bib49","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00280-011-1582-3","article-title":"Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFR\u03b1-positive chronic eosinophilic leukaemia","volume":"67","author":"Helbig","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"2025041711220492400_bib50","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1038\/leu.2012.162","article-title":"Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome","volume":"26","author":"Pardanani","year":"2012","journal-title":"Leukemia"},{"issue":"5","key":"2025041711220492400_bib51","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/MD.0b013e3182a71eba","article-title":"The spectrum of FIP1L1-PDGFRA-associated chronic eosinophilic leukemia: new insights based on a survey of 44 cases","volume":"92","author":"Legrand","year":"2013","journal-title":"Medicine (Baltim)"},{"issue":"3","key":"2025041711220492400_bib52","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/bloodadvances.2019001111","article-title":"Treatment-free remission in FIP1L1-PDGFRA-positive myeloid\/lymphoid neoplasms with eosinophilia after imatinib discontinuation","volume":"4","author":"Metzgeroth","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"2025041711220492400_bib53","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2003-08-2798","article-title":"Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"issue":"2","key":"2025041711220492400_bib54","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2008.07033.x","article-title":"A\u00a0single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients","volume":"141","author":"Helbig","year":"2008","journal-title":"Br J Haematol"},{"issue":"1","key":"2025041711220492400_bib55","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1365-2141.2008.07546.x","article-title":"Weekly imatinib dosage for chronic eosinophilic leukaemia expressing FIP1L1-PDGFRA fusion transcript: extended follow-up","volume":"145","author":"Helbig","year":"2009","journal-title":"Br J Haematol"},{"issue":"4","key":"2025041711220492400_bib56","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood-2006-02-004457","article-title":"Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant","volume":"108","author":"Lierman","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2025041711220492400_bib57","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/leu.2009.2","article-title":"FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib","volume":"23","author":"Lierman","year":"2009","journal-title":"Leukemia"},{"issue":"2","key":"2025041711220492400_bib58","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.1097\/HS9.0000000000000182","article-title":"FIP1L1-PDGFR\u03b1 p.T674I-D842L: a novel and ponatinib resistant compound mutation in FIP1L1-PDGFR\u03b1 positive leukemia","volume":"3","author":"Lierman","year":"2019","journal-title":"Hemasphere"},{"issue":"1","key":"2025041711220492400_bib59","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/leu.2011.181","article-title":"Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation","volume":"26","author":"Metzgeroth","year":"2012","journal-title":"Leukemia"},{"issue":"8","key":"2025041711220492400_bib60","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.3109\/10428194.2012.749469","article-title":"Sorafenib is effective for imatinib-resistant FIP1L1\/PDGFRA T674I mutation-positive acute myeloid leukemia with eosinophilia","volume":"54","author":"Al-Riyami","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2025041711220492400_bib61","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S1470-2045(20)30269-2","article-title":"Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial","volume":"21","author":"Heinrich","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10","key":"2025041711220492400_bib62","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1182\/blood-2007-07-100164","article-title":"Relapse following discontinuation of imatinib mesylate therapy for FIP1L1\/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing","volume":"110","author":"Klion","year":"2007","journal-title":"Blood"},{"issue":"22","key":"2025041711220492400_bib63","doi-asserted-by":"crossref","first-page":"33229","DOI":"10.18632\/oncotarget.8906","article-title":"Long-term outcomes of imatinib in patients with FIP1L1\/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China","volume":"7","author":"Qu","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"2025041711220492400_bib64","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3109\/10428194.2015.1065983","article-title":"Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript","volume":"57","author":"Helbig","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2025041711220492400_bib65","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1038\/leu.2017.240","article-title":"Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia","volume":"31","author":"Jawhar","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"2025041711220492400_bib66","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1080\/10428194.2018.1480774","article-title":"Cryptic ETV6-PDGFRB fusion in a highly complex rearrangement of chromosomes 1, 5, and 12 due to a chromothripsis-like event in a myelodysplastic syndrome\/myeloproliferative neoplasm","volume":"60","author":"Singh","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"2025041711220492400_bib67","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cancergen.2020.03.002","article-title":"Myeloid neoplasm with a novel cryptic PDGFRB rearrangement detected by next-generation sequencing","volume":"244","author":"Zimmermann","year":"2020","journal-title":"Cancer Genet"},{"key":"2025041711220492400_bib68","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cancergen.2023.01.002","article-title":"Rare and potentially fatal - cytogenetically cryptic TNIP1::PDGFRB and PCM1::FGFR1 fusion leading to myeloid\/lymphoid neoplasms with eosinophilia in children","volume":"272-273","author":"Berking","year":"2023","journal-title":"Cancer Genet"},{"key":"2025041711220492400_bib69","first-page":"100367","article-title":"Case of cryptic TNIP1::PDGFRB rearrangement presenting with myelodysplastic syndrome achieved hematologic and cytogenetic remission with low-dose imatinib plus decitabine therapy","volume":"19","author":"Qu","year":"2023","journal-title":"Leuk Res Rep"},{"key":"2025041711220492400_bib70","doi-asserted-by":"crossref","first-page":"8324791","DOI":"10.1155\/2016\/8324791","article-title":"Myeloid neoplasms with t(5;12) and ETV6-ACSL6 gene fusion, potential mimickers of myeloid neoplasm with PDGFRB rearrangement: case report with imatinib therapy and review of the literature","volume":"2016","author":"De Luca-Johnson","year":"2016","journal-title":"Case Rep Med"},{"issue":"1","key":"2025041711220492400_bib71","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1080\/16078454.2022.2117206","article-title":"Myeloid neoplasm with ETV6::ACSl6 fusion: landscape of molecular and clinical features","volume":"27","author":"Su","year":"2022","journal-title":"Hematology"},{"key":"2025041711220492400_bib72","doi-asserted-by":"crossref","first-page":"887945","DOI":"10.3389\/fonc.2022.887945","article-title":"A\u00a0novel IL3-ETV6 fusion in chronic eosinophilic leukemia not otherwise specified with t(5; 12) (q31; p13): a case report and literature review","volume":"12","author":"Zhao","year":"2022","journal-title":"Front Oncol"},{"issue":"23","key":"2025041711220492400_bib73","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1182\/blood-2014-02-555607","article-title":"Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib","volume":"123","author":"Cheah","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2025041711220492400_bib74","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2006-05-024828","article-title":"Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders","volume":"109","author":"David","year":"2007","journal-title":"Blood"},{"issue":"7","key":"2025041711220492400_bib75","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta","volume":"347","author":"Apperley","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2025041711220492400_bib76","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1600-0609.2012.01799.x","article-title":"Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement","volume":"89","author":"Arefi","year":"2012","journal-title":"Eur J Haematol"},{"issue":"20","key":"2025041711220492400_bib77","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood-2017-11-817510","article-title":"PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia","volume":"131","author":"Zhang","year":"2018","journal-title":"Blood"},{"issue":"10","key":"2025041711220492400_bib78","first-page":"1628","article-title":"A\u00a0new myeloproliferative disorder associated with\u00a0chromosomal translocations involving 8p11: a review","volume":"9","author":"Macdonald","year":"1995","journal-title":"Leukemia"},{"issue":"7","key":"2025041711220492400_bib79","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood.V85.7.1881.bloodjournal8571881","article-title":"A\u00a0syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia\/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity","volume":"85","author":"Inhorn","year":"1995","journal-title":"Blood"},{"key":"2025041711220492400_bib80","doi-asserted-by":"crossref","first-page":"1015792","DOI":"10.3389\/fonc.2022.1015792","article-title":"The 8p11 myeloproliferative syndrome: genotypic and phenotypic classification and targeted therapy","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"issue":"8","key":"2025041711220492400_bib81","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/10245332.2018.1446279","article-title":"Clinical outcomes of myeloid\/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement","volume":"23","author":"Umino","year":"2018","journal-title":"Hematology"},{"issue":"40","key":"2025041711220492400_bib82","doi-asserted-by":"crossref","first-page":"14479","DOI":"10.1073\/pnas.0404438101","article-title":"PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder","volume":"101","author":"Chen","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2025041711220492400_bib83","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3324\/haematol.2012.066407","article-title":"Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome","volume":"98","author":"Chase","year":"2013","journal-title":"Haematologica"},{"issue":"5","key":"2025041711220492400_bib84","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/ejh.12957","article-title":"Primary cells in BCR\/FGFR1-positive 8p11 myeloproliferative syndrome are sensitive to dovitinib, ponatinib, and dasatinib","volume":"99","author":"Landberg","year":"2017","journal-title":"Eur J Haematol"},{"issue":"4","key":"2025041711220492400_bib85","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1634\/theoncologist.2016-0354","article-title":"Response to tyrosine kinase inhibitors in myeloproliferative neoplasia with 8p11 translocation and CEP110-FGFR1\u00a0rearrangement","volume":"22","author":"Wehrli","year":"2017","journal-title":"Oncol"},{"issue":"23","key":"2025041711220492400_bib86","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/blood.V126.23.2812.2812","article-title":"Limited efficacy of ponatinib in myeloproliferative neoplasms associated with FGFR1 fusion genes [abstract]","volume":"126","author":"Kreil","year":"2015","journal-title":"Blood"},{"issue":"13","key":"2025041711220492400_bib87","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1182\/bloodadvances.2020002308","article-title":"Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia","volume":"4","author":"Kasbekar","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"2025041711220492400_bib88","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1158\/0008-5472.CAN-04-4263","article-title":"The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2","volume":"65","author":"Reiter","year":"2005","journal-title":"Cancer Res"},{"issue":"7","key":"2025041711220492400_bib89","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ajh.25825","article-title":"Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes","volume":"95","author":"Schwaab","year":"2020","journal-title":"Am J Hematol"},{"issue":"17","key":"2025041711220492400_bib90","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1200\/JCO.2012.46.4370","article-title":"Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene","volume":"31","author":"Rumi","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2025041711220492400_bib91","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00277-015-2451-7","article-title":"Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene","volume":"94","author":"Rumi","year":"2015","journal-title":"Ann Hematol"},{"issue":"8","key":"2025041711220492400_bib92","doi-asserted-by":"crossref","first-page":"e661","DOI":"10.1093\/oncolo\/oyac072","article-title":"PCM1-JAK2 fusion tyrosine kinase gene-related neoplasia: a systematic review of the clinical literature","volume":"27","author":"Kaplan","year":"2022","journal-title":"Oncol"},{"issue":"8","key":"2025041711220492400_bib93","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2011-03-343426","article-title":"Response of ETV6-FLT3-positive myeloid\/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3","volume":"118","author":"Walz","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2025041711220492400_bib94","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1038\/s41379-021-00817-7","article-title":"Myeloid\/lymphoid neoplasms with FLT3 rearrangement","volume":"34","author":"Tang","year":"2021","journal-title":"Mod Pathol"},{"issue":"10","key":"2025041711220492400_bib95","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1038\/leu.2014.168","article-title":"ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant","volume":"28","author":"Falchi","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"2025041711220492400_bib96","doi-asserted-by":"crossref","first-page":"a006243","DOI":"10.1101\/mcs.a006243","article-title":"A\u00a0TRIP11:: FLT3 gene fusion in a patient with myeloid\/lymphoid neoplasm with eosinophilia and tyrosine kinase gene fusions: a case report and review of the literature","volume":"9","author":"Venable","year":"2023","journal-title":"Cold Spring Harb Mol Case Stud"},{"issue":"9","key":"2025041711220492400_bib97","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.3324\/haematol.2016.144345","article-title":"Characterization of leukemias with ETV6-ABL1 fusion","volume":"101","author":"Zaliova","year":"2016","journal-title":"Haematologica"},{"issue":"10","key":"2025041711220492400_bib98","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2004-03-0787","article-title":"FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia","volume":"104","author":"Pardanani","year":"2004","journal-title":"Blood"},{"issue":"1","key":"2025041711220492400_bib99","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/16078454.2020.1854493","article-title":"Myeloid\/lymphoid neoplasm with CEP110-FGFR1 fusion: an analysis of 16 cases show common features and poor prognosis","volume":"26","author":"Chen","year":"2021","journal-title":"Hematology"},{"key":"2025041711220492400_bib100","doi-asserted-by":"crossref","first-page":"106460","DOI":"10.1016\/j.leukres.2020.106460","article-title":"Myeloid\/lymphoid neoplasms with eosinophilia and FLT3 rearrangement","volume":"99","author":"Shao","year":"2020","journal-title":"Leuk Res"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/16\/1758\/2369448\/blood_bld-2023-022417-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/16\/1758\/2369448\/blood_bld-2023-022417-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T15:22:21Z","timestamp":1744903341000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/16\/1758\/517142\/How-I-diagnose-and-treat-myeloid-lymphoid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":100,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2025,4,17]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023022417","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]}}}